Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $41.67.

Several equities research analysts recently commented on RPRX shares. Citigroup lowered their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, October 25th. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RPRX. Blue Trust Inc. lifted its holdings in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 943 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Royalty Pharma during the third quarter worth $61,000. EverSource Wealth Advisors LLC raised its stake in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 655 shares during the last quarter. Transamerica Financial Advisors Inc. boosted its holdings in Royalty Pharma by 99.9% in the 3rd quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,729 shares during the period. Finally, iA Global Asset Management Inc. grew its position in Royalty Pharma by 274.7% in the 2nd quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company's stock worth $168,000 after purchasing an additional 4,683 shares during the last quarter. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Down 2.6 %

NASDAQ RPRX traded down $0.65 on Wednesday, reaching $24.47. The stock had a trading volume of 3,732,111 shares, compared to its average volume of 2,664,242. Royalty Pharma has a 1 year low of $24.46 and a 1 year high of $31.66. The business has a 50 day moving average price of $26.55 and a 200 day moving average price of $27.19. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $14.42 billion, a price-to-earnings ratio of 12.68, a P/E/G ratio of 4.36 and a beta of 0.46.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date was Friday, November 15th. Royalty Pharma's dividend payout ratio is 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.